NeuroPace, Inc.
NASDAQ:NPCE · NASDAQ Global Market
+$0.05 today
Vol 0.13M · Avg 0.18M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-112.8%
avg -108.0%
ROIC
-18.2%
avg -58.7%
ROA
-20.3%
avg -47.6%
Analysis
ROIC is currently the strongest return metric at -18.2% versus its period average of -58.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Joel D. Becker | Chief Executive Officer, President & Director | $1.12M | — | 58 | $140,436.00 | 0.41% |
Martha J. Morrell | Chief Medical Officer | $725,315.00 | — | 69 | $52,385.00 | 0.15% |
Patrick F. Williams | Chief Financial Officer | $689,414.00 | — | 53 | $68,670.00 | 0.20% |
Rebecca L. Kuhn | Advisor | $588,399.00 | — | 65 | $131,613.00 | 0.39% |
Scott R. Schaper | Head of Investor Relations | — | — | — | $5,368.00 | 0.02% |
Chris Reese | Senior Vice President of Sales | — | — | — | — | — |
Dylan John | Chief of Operations & Development | — | — | — | — | — |
Amy Treadwell | Vice President of Human Resources | — | — | — | — | — |
Katie Keller | Vice President of Marketing | — | — | — | — | — |
Leah Akin | General Counsel & Corporate Secretary | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
1
$399,250.00
Net Sentiment
$399,250.00
Net selling
Most Active
Morrell Martha
1 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 1 sells worth $399,250.00 over the last 12 months. That adds up to net selling of $399,250.00. Morrell Martha was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +16.7% | +18.4% (7yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +16.7% over three years. Forward estimates point to Revenue at +18.4% (7yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
BrainsWay Ltd.
NASDAQ:BWAY
$567.07M
Cerus Corporation
NASDAQ:CERS
$529.98M
Delcath Systems, Inc.
NASDAQ:DCTH
$404.77M
908 Devices Inc.
NASDAQ:MASS
$329.54M
Sight Sciences, Inc.
NASDAQ:SGHT
$280.48M
Senseonics Holdings, Inc.
NASDAQ:SENS
$272.08M
RxSight, Inc.
NASDAQ:RXST
$194.77M
CVRx, Inc.
NASDAQ:CVRX
$130.29M
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
$116.72M
Genelux Corporation
NASDAQ:GNLX
$108.34M
Who manages NPCE?
NeuroPace, Inc. (NPCE) lists 10 active executives. The top listed executive is Scott R. Schaper, Head of Investor Relations.
Are NPCE insiders buying or selling?
Recent insider activity shows net selling of $55.40M.
Explore More
Continue the stock analysis
Jump to another research area for this company.